Cyclin D1 and human neoplasia

Journal of Clinical Pathology - Molecular Pathology

Volumn 51, Issue 1, 1998, Pages 1-7

  Donnellan, R ^a   Chetty, R ^a  

^a UNIVERSITY OF NATAL   (South Africa)

Author keywords

Cell cycle; Cyclin D1; Neoplasia

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN;

BREAST CANCER; CANCER; CANCER CYTODIAGNOSIS; CARCINOGENESIS; CELL CYCLE; COLORECTAL CANCER; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT TRANSFORMATION; MANTLE CELL LYMPHOMA; ONCOGENE; PRIORITY JOURNAL; REVIEW; SKIN CANCER; UROGENITAL TRACT CANCER;

EID: 0031895560     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.51.1.1     Document Type: Review

References (151)

1. Willis RA. The spread of tumors in the human body. London: Butterworth and Co, 1952.
2. Johnson DG, Richie E, Conti C. The cell cycle and cancer. Cancer Bull 1995;47:480-5.
3. Clurman BE, Roberts JM. Cell cycle and cancer. J Nat Cancer Inst 1995;87:1499-501.
4. Hunter T, Pines J. Cyclins and cancer 2: cyclin D and CDK inhibitors come of age. Cell 1994;79:573-82.
5. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994;79:551-5.
6. Cordon-Cardo C. Mutations of cell cycle regulators: biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-60.
7. Peters G. The D-type cyclins and their role in tumorigenesis. J Cell Sci 1994;18:89-96.
8. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin dependent kinases. Genes Dev 1995;9:1149-63.
9. Hirama T, Koeffler HP. The role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86:841-54.
10. Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 1993;259:1908-12.
11. Quelle DE, Ashmun RA, Shurtleff SA. Overexpression of mouse D-type cvclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993;7:1559-71.
12. Resnitzky D, Gossen M, Bujard H. Acceleration of the G1/S phase transition by expression of cvclins D1 and E with an inducible system. Mol Cell Biol 1994;14:1669-79.
13. Friend SH, Horowitz JM, Gerber MR. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organisation of the sequence and its encoded protein. Proc Natl Acad Sci USA 1987;84:9059-63.
14. Lee W-H, Shew J, Hong FD. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 1987;329:642-5.
15. Fung Y-K, Murphree A, T'Ang A. Structural evidence for the authenticity of the human retinoblastoma gene. Science 1987;236:1657-61.
16. De Caprio JM, Ludlow J, Lynch D. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 1989;58:1085-95.
17. Buchkovich K, Duffy L, Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 1989;58:1097-105.
18. Chen P, Scully P, Shew J-Y. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 1989;58:1193-8.
19. Hinds PW, Weinberg RA. Tumor suppressor genes. Curr Opin Genet Dev 1994;4:135-41.
20. Kaelin WG, Pallas DC, De Caprio JA, et al. Identification of the cellular proteins that can react specifically with the E1A-binding region of the retinoblastoma gene product. Cell 1991;64:521-32.
21. DeFeo-Jones D, Huang PS, Jones RE, et al. Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product. Nature 1991;352:251-4.
22. Chellappan SP, Hiebert S, Mudryj M, et al. The E2F transcription factor is a cellular target for the RB protein. Cell 1991;65:1053-61.
23. Nevins JR. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992;258:424-9.
24. Dowdy SF, Hinds PW, Louie K, et al. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993;73:499-511.
25. Ewen ME, Sluss HK, Sherr CJ, et al. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993;73:487-97.
26. Kato J, Matsushime H, Hiebert SW, et al. Direct binding of cyclin D to the retinoblastoma gene product (pRB) and pRB phosphorylation by the cyclin D-dependent Cdk4. Genes Dev 1993;7:331-42.
27. Hinds PW, Mittnacht S, Dulic V, et al. Regulation of retinoblastoma protein functions by extopic expression of human cyclins. Cell 1992;70:993-100b.
28. Jiang W, Khan SM, Zhou P, et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 1993;8:3447-57.
29. Bates S, Parry D, Bonnetta L, et al. Absence of cyclin D Cdk complexes in cells lacking functional retinoblastoma protein. Oncogene 1994;9:1633-40.
30. Tam SW, Theodoras AM, Shay JW, et al. Differential expression and regulation ol cyclin D1 protein in normal and tumor cells: association with Cdk4 is required for cyclin D1 function in G1 progression. Oncogene 1994;9:266-374.
31. Muller H, Lukas J, Schneider A, et al. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci USA 1994;91:2945-9.
32. Lukas J, Muller H, Bartkova J, et al. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1.J Cell Biol 1994;125:625-38.
33. Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a bcl-1 linked candidate oncogene. Nature 1991;350:512-15.
34. Hsi ED, Zukerberg LR, Yang WI, et al. Cyclin D1 PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Endocrinol Metabol 1996;81:1736-9.
35. Rosenberg CL, Wong E, Petty EM, et al. PRAD1, a candidate bcl1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 1991;88: 9638-42.
36. Lammie GA, Fantl V, Smith R, et al. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 1991;6:439-44.
37. Meeker TC, Grimaldi JC, O'Rourke R, et al. An additional breakpoint in the bell locus associated with the t(11; 14)(q13;q32) translocation of a B-cell malignancy. Blood 1989;74:1801-6.
38. Withers DA, Harvey RC, Faust JB, et al. Characterization of a candidate bcl-1 gene. Mol Cell Biol 1991;11:4846-53.
39. Schuuring E, Verhoeven E, Mooi WJ, et al. Identification and cloning of two overexpressed genes, U21B31 PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 1992;7:355-61.
40. Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes a review. Gene 1995;159: 83-96.
41. Hall M, Peters G. Genetic alterations of cyclins, cyclindependent kinases, and cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108.
42. Rosenberg CL, Motokura T, Kronenberg H, et al. Coding sequence of the overexpressed transcript of the putative oncogene Prad 1 cyclin D1 in two primary human tumors. Oncogene 1993;8:519-21.
43. Rimokh R, Berger F, Bastard C. et al. Rearrangement of CCND1 (BCL1 PRAD1) 3' untranslated region in mantle cell lymphomas and t11q13-associated leukaemias. Blood 1994;83:3689-6.
44. Rimokh R, Berger F, Delsol G, et al. Rearrangements and overexpression of the bcl-1 PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukaemias. Blood J 1993;81:3063-7.
45. Bosch F, Jares P, Campo E, et al. PRAD-1 cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994;84:2762-32.
46. Hayashi T, Ohno H, Yamabe H, et al. Clinical aspects of B-cell malignancy involving the BCL-PRAD-1 locus. Int J Hamatol 1994;59:281-96.
47. de Boer CJ, Schuuring E, Dreef E, et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma Blood 1995;86:2715-23.
48. de Boer CJ, van Krieken JH, Kluin-Nelemans HC, et al. Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene 1995;10:1833-40.
49. Banno S, Yoshikawa K, Nakamura S, et al. Monoclonal antibody against PRAD1 cyclin D1 stains nuclei of tumor cells with translocation or amplification at BCL-1 locus. Jpn J Cancer Res 1994;85:918-26.
50. Oka K, Ohno T, Kita K, et al. PRAD1 gene over-expression in mantle cell lymphoma hut not in other low-grade B-cell lymphomas including extranodal lymphoma. Br J Haematol 1994;86:786-91.
51. Nakamura S, Seto M, Banno S, et al. Immunohistochemical analysis of cyclin D1 protein in hematopoeitic neoplasms with special reference to mantle cell lymphomas. Jpn J Cancer Res 1994;85:1270-9.
52. Swerdlow SH, Yang WI, Zukerberg LR, et al. Expression of cyclin D1 protein in centrocytic mantle cell lymphomas with and without rearrangement of the BCL1 cyclin D1 gene. Hum Pathol 1995;26:999-1004.
53. Kuroda H, Komatsu H, Nakamura S, et al. The positive nuclear staining observed with monoclonal antibody against PRAD1/cyclin D1 correlates with mRNA expression in mantle cell lymphoma. Jpn J Cancer Res 1995;86:890-8.
54. Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma: a proposal for unification of morphologic, immunologic and molecular data. Am J Surg Pathol 1992;16:637-40.
55. Vasef MA, Medeiros LJ, Yospur LS, et al. Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol 1997;10:927-32.
56. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
57. Nakamura S, Yatahe Y, Kuroda H, et al. Immunostaining of PRAD1/cyclin D1 protein as a marker for the diagnosis of mantle cell lymphoma. Leukemia 1997;11:536-7.
58. Ott G, Kalla J, Ott MM, et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 1997;89:1421-9.
59. Kumar S, Krenacs L, Otsuki T, et al bcl-1 rearrangement and cyclin D1 protein expression in multiple lymphomatous polyposis. Am J Clin Pathol 1996;105:737-43.
60. Gillet C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994;54:1812-17.
61. Bartkova J, Lukas J, Muller H, et al. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994;57:353-61.
62. Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8:2127-33.
63. Zhang SY, Caamano J, Cooper F, et al. Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol 1994;102:695-8.
64. Adnane J, Gaudray P, Simon MP, et al. Proto-oncogene amplification and human breast tumor phenotype. Oncogene 1989;4:1389-95.
65. Tang RP, Kacinski B, Validire P, et al. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells? J Cell Biocham 1990;44:189-98.
66. Schuuring F, Verhoeven E, van Tinteren H, et al. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 1992;52:5229-34.
67. Frierson HF Jr, Gaffey MJ, Zukerberg LR, et al. Immunohistochemical detection and gene amplification of cyclin D1 in mammary infiltrating ductal carcinoma. Mod Pathol 1996;9:725-30.
68. Fantl V, Richards MA, Smith R, et al. Gene amplification on chromosome band q13 and oestrogen receptor status in breast cancer. Eur J Cancer 1990;26:423-9.
69. Borg A, Sigurdsson H, Clark GM, et al. Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer 1991;63:136-42.
70. Berns EM, Klijn JG, van Staveren IL, et al. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors, Eur J Cancer 1992;28:697-700.
71. Michalides R, Hageman P, van Tinteren H, et al. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996;73:728-34.
72. Gillett C, Smith P, Gregory W, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996;69:92-9.
73. Nielsen NH, Emdin SO, Landberg G. Deregulation of G1 cyclins and pRB alterations in estrogen receptor negative breast cancer with poor prognosis. Proc Am Assoc Cancer Res 1996;37:28.
74. Pelosio P, Barbareschi M, Bonoldi E, et al. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol 1996;7:695-703.
75. Courjal F, Louason G, Speiser P, et al. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 1996;69:247-53.
76. Barbareschi M, Pelosio P, Caffo O, et al. Cyclin D1 gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21 WAF1 immunohistochemical expression. Int J Cancer 1997;74:171-4.
77. van Dierst PJ, Michalides RJ, Jannink L, et al. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 1997;150:705-11.
78. Fantl V, Stamp G, Andrews A, et al. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 1995;9:2364-72.
79. Sicinski P, Donaher JL, Parker SB. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995;82:621-30.
80. Dees C, Foster JS, Ahamed S, et al. Dietary estrogens stimulate human breast cells to enter the cell cycle. Environ Health Perspect 1997;3:633-6.
81. Zwijsen RM, Wientjens E, Klompmaker R, et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997;88:405-15.
82. Simpson JF, Quan DE, O'Malley F, et al. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol 1997; 151:101-8.
83. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995;345:1154-7.
84. McIntosh GG, Anderson JJ, Milton I, et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 1995;11:885-91.
85. Nielsen NH, Emdin SO, Cajander J, et al. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 1997;14: 295-304.
86. Wakasugi E, Kobayashi T, Tamaki V, et al. Analysis of phosphorylation of pRB and its regulatory proteins in breast cancer. J Clin Pathol 1997;50:407-12.
87. Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions [see comments]. Nat Med 1995;1:1257-60.
88. Callander T, EI Naggar AK, Lee MS, et al. PRAD1 (CCND1/cyclin D1) oncogene amplification in primary head and neck squamous carcinoma. Cancer 1994;74:152-8.
89. Jones P, Fernandez P, Campo P. PRAD1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 1994;54:4183-7.
90. Bartkova J, Lukas J, Muller H, et al. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 1995;55:949-56.
91. Michalides R, van Veelen N, Hart A, et al. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995;55:975-8.
92. Fracchiolla NS, Pruneri G, Pignataro L, et al. Molecular and immunohistochemical analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas: correlation of protein expression with lymph node metastases and advanced clinical stage. Cancer 1997;79:1114-21.
93. Michalides RJ, van Veelen NM, Kristel PM, et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1997;123:497-502.
94. Akervall JA, Michalides RJ, Mineta H, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 1997;79:380-9.
95. Masuda M, Hirakawa N, Nakashima T, et al. Cyclin D1 overexpression in primary hypopharyngeal carcinomas. Cancer 1996;78:390-5.
96. Tsuda T, Tahara E, Kajiyama G, et al. High incidence of coamplification of hst-1 and int-2 genes in human esophageal carcinomas. Cancer Res 1989;49:5505-8.
97. Jiang W, Kahn SM, Tomita N, et al. Amplification and expression of the human cyclin D gene in esophageal cancer Cancer Res 1992;52:2980-3.
98. Jiang W, Zhang YJ, Kahn SM, et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 1993;90:9026-30.
99. Naitoh H, Shibata J, Kawaguchi A, et al. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol 1995;146:1161-9.
100. Kitagawa Y, Ueda M, Ando N, et al. Significance of int-2 hst-1 coamplification as a prognostic factor in patients with esophageal squamous carcinoma. Cancer Res 1991;51: 1504-8.
101. Shinozaki H, Ozawa S, Ando N, et al. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding new gene information. Clin Cancer Res 1995;2:1155-61.
102. Zhou P, Jiang W, Zhang YJ, et al. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 1995;11:571-80.
103. Chetty R, Chetty S. Cyclin D1 and retinohlastoma protein expression in oesophageal squamous cell carcinoma. J Clin Pathol: Mol Pathol 1997;50:257-60.
104. Zhang YJ, Jiang W, Chen CJ, et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 1993;196:1010-16.
105. Nishida N, Fukuda Y, Komeda T, et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994;54:3107-10.
106. Rogler CE. Cellular and molecular mechanisms of hepatocarcinogenesis associated with hepadnavirus infection. Curr Top Microbiol Immunol 1991;168:103-40.
107. Hatada I, Tokino T, Ochiya T, et al. Co-amplification of integrated hepatitis B virus DNA and transforming gene hst-1 in a hepatocellular carcinoma. Oncogene 1988;3:537-40.
108. Nakamura T, Tokino T, Nagaya T, et al. Microdeletion associated with the integration process of hepatitis B virus DNA. Nuclcic Acids Res 1988;16:4865-73.
109. Leach F, Elledge S, Sherr C, et al. Amplification of cyclin genes in colorectal carcinomas. Cancer Res 1993;53:1986-9.
110. Maeda K, Chung YS, Kang SM, et al. Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer 1997;74:310-15.
111. Arber N, Hibshoosh H, Moss SF, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996;110:669-74.
112. Zhang T, Nanney LB, Luongo C, et al. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res 1997;57:169-75.
113. Arber N, Doki Y, Han EK, et al. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 1997;57:1569-74.
114. Tsutsumi M, Sakamoto H, Yoshida T, et al. Coamplification of the hst-1 and int-2 genes in human cancers. Jpn J Cancer Res 1988;79:428-32.
115. Theillet C, Le Roy X, De Lapeyriere O, et al. Amplification of FGF-related genes in human tumors: possible involvement of HST in breast carcinomas [erratum published in Oncogene 1989;4:1537]. Oncogene 1989;4:915-22.
116. Proctor AJ, Coombs LM, Cairns JP, et al. Amplification at chromosome q13 in transitional cell tumours of the bladder. Oncogene 1991;6:789-95.
117. Lee CC, Yamamoto S, Morimura K, et al. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer 1997;79:780-9.
118. Shin KY, Kong G, Kim WS, et al. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer 1997;75:1788-92.
119. Kurzrock R, Ku S, Talpaz M. Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines. Cancer 1995;75:584-90.
120. Nichols GE, Williams ME, Gaffey MJ, et al. Cyclin D1 gene expression in human cervical neoplasia. Mod Pathol 1996;9:418-25.
121. Bartkova J, Lukas J, Strauss M, et al. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995;10:775-8.
122. Nikaido T, Li SF, Shiozawa T, et al. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 1996;78:1248-53.
123. Barbieri F, Cagnoli M, Ragni N, et al. Expression of cyclin D1 correlates with malignancy in human ovarian tumours. Br J Cancer 1997;75:1263-8.
124. Hung WC, Chai CY, Huang JS, et al. Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors. Hum Pathol 1996;27:1324-8.
125. Worsley SD, Ponder BA, Davies BR. Overexpression of cyclin D1 in epithelial ovarian cancers [see comments]. Gynecol Oncol 1997;64:189-95.
126. Peeper DS, Upton TM, Ladha MH, et al. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein [erratum published in Nature 1997;386:521]. Nature 1997;386:177-81.
127. Downward J. Cell cycle: routine role for Ras. Curr Biol 1997;7:R258-60.
128. Berenson JR, Koga H, Yang J, et al. Frequent amplification of the bcl-1 locus in poorly differentiated squamous cell carcinoma of the lung. The Lung Cancer Study Group. Oncogene 1990;5:1343-8.
129. Mate JL, Ariza A, Aracil C, et al. Cyclin D1 overexpression in non-small cell lung carcinoma: correlation with Ki67 labelling index and poor cytoplasmic differentiation. J Pathol 1996;180:395-9.
130. Yang WI, Chung KY, Shin DH, et al. Cyclin D1 protein expression in lung cancer. Yonsei Med J 1996;37:142-50.
131. Betticher DC, Heighway J, Hasleton PS, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 1996;73:294-300.
132. Kwa HB, Michalides RJ, Dijkman JH, et al. The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer. Lung Cancer 1996;14:207-17.
133. Betticher DC, Heighway J, Thatcher N, et al. Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients. Br J Cancer 1997;75: 1761-8.
134. Inohara S, Kitagawa K, Kitano Y. Expression of cyclin D1 and p53 protein in various malignant skin tumors. Dermatology 1996;192:94-8.
135. Zhang SY, Liu SC, Goodrow T, et al. Increased expression of G1 cyclins and cyclin-dependent kinases during tumor progression of chemically induced mouse skin neoplasms. Mol Carcinog 1997;18:142-52.
136. Maelandsmo GM, Berner JM, Florenes VA, et al. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas - relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 1995;72:393-8.
137. Welcker M, Lukas J, Strauss M, et al. Enhanced protein stability: a novel mechanism of D-type cyclin overabundance identified in human sarcoma cells. Oncogene 1996;13:419-25.
138. Dicks PB, Hubbard SL, Murakami M, et al. Cyclin and cyclin-dependent kinase expression in human astrocytoma cell lines. J Neuropathol Exp Neurol 1997;56:201-300.
139. He J, Allen JR, Collins VP, et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994;54:5804-7.
140. Wang LD, Shi ST, Zhou Q, et al. Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer 1994;59:514-19.
141. Nakagawa H, Wang TC, Zukerberg L, et al. The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach. Oncogene 1997;14:1185-90.
142. Gansauge S, Gansauge F, Ramadani M, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997;57:1634-7.
143. Tsuda T, Nakatani H, Tahara E, et al. HST1 and INT2 gene coamplification in a squamous cell carcinoma of the gallbladder. Jpn J Clin Oncol 1989;19:26-9.
144. Boggild MD, Jenkinson S, Pistorello M, et al. Molecular genetic studies of sporadic pituitary tumors. J Clin Endocrinol Metabol 1994;78:387-92.
145. Latil A, Baron JC, Cussenot O, et al. Oncogene amplifications in early-stage human prostate carcinomas. Int J Cancer 1994;59:637-8.
146. Clayton RN, Boggild M, Bates AS, et al. Tumour suppressor genes in the pathogenesis of human pituitary tumours. Hormone Res 1997;47:185-93.
147. Park SK, Kang SK, Lee DY, et al. Temporal expressions of cyclins and cyclin dependent kinases during renal development and compensatory growth. Kidney Int 1997;51:762-9.
148. Betticher DC. Cyclin D1, another molecule of the year? [editorial]. Ann Oncol 1996;7:223-5.
149. Barnes DM. Cyclin D1 in mammary carcinoma. J Pathol 1997;181:267-9.
150. Weinstein IB. Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. J Cell Biochem 1996;25(suppl):23-8.
151. Ligueros M, Jeoung D, Tang B, et al. Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells. Br J Cancer 1997;76:21-8.